Quinoxaline containing medicaments for post exposure prophylaxis of an HIV infection
OwnerKazuyasu Mori, Yasuhiro Yasutomi +3inventors
InventorsKazuyasu Mori, Yasuhiro Yasutomi, Kazushiqe Sugama, Shuzo Sawada, Helga Rubsamen-Waigmann
Life of this patent
Estimating the term…
Abstract
Disclosed is the use of an antiviral substance which, when given alone for 14 days, shows a mean initial suppression of viral load by 1.4 log or more and which does not reduce the number of lymphocytes, granulocytes and macrophages as determined by differential blood count after 12 weeks of treatment for the manufacture of a medicament for the immune system-assisted post-exposure prophylaxis of an HIV infection.
Claims15
The use of an antiviral substance which, when given alone for 14 days, shows a mean initial suppression of viral load by 1.4 log or more and which does not reduce the number of lymphocytes, granulocytes and macrophages as determined by differential blood count after 12 weeks of treatment
- for the manufacture of a medicament for the immune system-assisted post-exposure prophylaxis of an HIV Infection.
The use of an antiviral substance, which is a non-nucleosidic reverse transcriptase inhibitor of formula (I) or a tautomer thereof or a pharmacologically acceptable derivative thereof:
- 5
- wherein the substituents and symbols have the following meanings:
- n=0, 1 or 2
- R1=F, Cl, HO, methoxy, ethoxy, n-propoxy, isopropoxy;
- R2=C1-C4 alkyl, optionally substituted with OH, C1-C4 alkoxy, or C1-C4 alkylthio;
- R3=C1-C6 alkyloxycarbonyl or C2-C6 alkenyloxycarbonyl
- X=O, S or Se.
- for the manufacture of a medicament for the immune system-assisted post-exposure prophylaxis of an HIV infection.
The use according to any preceding claim, wherein the post-exposure prophylaxis is started as soon as possible after a (suspected) exposure to HIV and before the complete development of a primary viremia and seroconversion.
The use according to any preceding claim, wherein the post-exposure prophylaxis is terminated after 12 weeks of start of therapy.
The use according to any preceding claim, wherein the post exposure prophylactic treatment establishes a specific immune surveillance sufficient to contain the viral load in a treated subject at a clinically acceptable level.
The use according to any preceding claim wherein the treatment is started after 72 h following exposure but before full development of a primary viremia and seroconversion.
The use according to any preceding claim, wherein the medicament is suited for once daily administration.
Dependencies are inferred from the claim text.